Media coverage about Hospira (NYSE:HSP) has been trending somewhat positive on Tuesday, according to Accern Sentiment. The research firm identifies negative and positive media coverage by analyzing more than 20 million blog and news sources. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Hospira earned a media sentiment score of 0.10 on Accern’s scale. Accern also gave news headlines about the healthcare company an impact score of 45.902421376841 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the next several days.
Hospira (NYSE HSP) opened at $89.96 on Tuesday. The company has a market cap of $15,560.00 and a price-to-earnings ratio of 37.64.
TRADEMARK VIOLATION WARNING: This piece of content was first posted by TrueBlueTribune and is owned by of TrueBlueTribune. If you are accessing this piece of content on another site, it was illegally copied and reposted in violation of U.S. and international trademark and copyright legislation. The correct version of this piece of content can be accessed at https://www.truebluetribune.com/2018/01/02/somewhat-favorable-news-coverage-somewhat-unlikely-to-affect-hospira-hsp-stock-price.html.
Hospira Company Profile
Hospira, Inc provides injectable pharmaceutical drugs and infusion technologies and it develops, manufactures, distributes and markets biosimilars. The Company’s portfolio includes generic acute-care and oncology injectables, biosimilars, and integrated infusion therapy and medication management products.
Receive News & Ratings for Hospira Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hospira and related companies with MarketBeat.com's FREE daily email newsletter.